Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
Drugs Health Pharma

Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal

Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.

Read More
Drugs Health Pharma

Pfizer’s drug helps people with rare lung cancer live longer, data shows

Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.

Read More
Drugs Health Pharma

Pfizer Inc. unveils a new $1.5 billion plan to cut costs as vaccine sales fall

Pfizer Inc., announced a $1.5 billion “multi-year” savings plan to cut costs of goods sold, on top of a similar $4 billion initiative.

Read More
Drugs Health Pharma

Pfizer, AstraZeneca to invest close to $1 billion in France to expand

HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.

Read More
Drugs Health Pharma

Boy dies during Pfizer’s clinical trial probing rare genetic disease

HQ Team May 8, 2024: A young boy, treated for a rare genetic disease, died during a mid-stage clinical trial conducted by Pfizer,.

Read More
Drugs Health Pharma

Pfizer gets full US regulatory approval for cervical cancer drug

HQ Team April 30, 2024: The US health regulator has approved Pfizer’s drug to treat cervical cancer patients whose disease has progressed beyond.

Read More
Drugs Health Pharma

EC marketing nod for Pfizer drug to fight antimicrobial resistance

HQ Team April 22, 2024: The European Commission has granted Pfizer Inc., marketing authorisation for a drug to treat adult patients with intra-abdominal.

Read More
Drugs Health Pharma

Last-stage trials achieve “positive” results for RSV drug: Pfizer says

HQ Team April 9, 2024: Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to.

Read More
Drugs Health Pharma

Pfizer says trials on lymphoma drug ‘positive,’ extends life of patients 

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

Read More
X